Back to Search
Start Over
Arctigenin induces activated HSCs quiescence via AMPK-PPARγ pathway to ameliorate liver fibrosis in mice.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2024 Jul 05; Vol. 974, pp. 176629. Date of Electronic Publication: 2024 Apr 26. - Publication Year :
- 2024
-
Abstract
- Arctigenin (ATG), a traditional Chinese herbal medicine, is a natural lignan compound extracted from the seeds of burdock (Arctium lappa L, Asteraceae). As a natural product with multiple biological activities, the effect and mechanism of ATG against liver fibrosis are not fully elucidated yet. In current work, we first discovered that ATG could improve CCl <subscript>4</subscript> -induced liver injury reflected by lower plasma ALT and AST levels, liver coefficient and pathological scoring of ballooning. Furthermore, it also could reduce the positive areas of Masson, Sirius red and α-SMA staining, inhibit the expression of fibrosis-related genes (Col1a1, Col3a1, Acta2), and decrease the content of hydroxyproline, indicated ATG treatment had benefits in alleviating CCl <subscript>4</subscript> -induced liver fibrosis. In vitro, we observed that ATG can inhibit collagen production stimulated by TGF-β1 in LX2 cells. By analysis of the information obtained from SymMap and GeneCards databases and in vitro validation experiments, ATG was proven to be an indirect PPARγ agonist and its effect on collagen production was dependent on PPARγ. Subsequently, we confirmed that ATG activating AMPK was the contributor of its effect on PPARγ and collagen production. Finally, the transformation of activated hepatic stellate cells was determined after treated with ATG, in which ATG treatment could return activated LX2 cells to quiescence because of the elevated quiescent markers and lipid droplets. Our work has highlighted the potential of ATG in the treatment of liver fibrosis and clarified that ATG can activate AMPK/PPARγ pathway to restore the activated hepatic stellate cell to quiescence thereby improving liver fibrosis.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Subjects :
- Animals
Mice
Male
Cell Line
Carbon Tetrachloride
Humans
Mice, Inbred C57BL
Liver drug effects
Liver pathology
Liver metabolism
Collagen metabolism
Lignans pharmacology
Lignans therapeutic use
Hepatic Stellate Cells drug effects
Hepatic Stellate Cells metabolism
Hepatic Stellate Cells pathology
Liver Cirrhosis drug therapy
Liver Cirrhosis pathology
Liver Cirrhosis metabolism
Furans pharmacology
Furans therapeutic use
AMP-Activated Protein Kinases metabolism
PPAR gamma metabolism
Signal Transduction drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 974
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38679116
- Full Text :
- https://doi.org/10.1016/j.ejphar.2024.176629